Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities
Dimitrios Patoulias, Alexandra Katsimardou, Konstantinos Stavropoulos, et al.
Current Hypertension Reports (2020) Vol. 22, Iss. 11
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Renin–Angiotensin System: An Important Player in the Pathogenesis of Acute Respiratory Distress Syndrome
Jaroslav Hrenak, Fedor Šimko
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 21, pp. 8038-8038
Open Access | Times Cited: 60
The Impact of the Renin-Angiotensin-Aldosterone System on Inflammation, Coagulation, and Atherothrombotic Complications, and to Aggravated COVID-19
Mikael Ekholm, Thomas Kahan
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 39
Effects of Bariatric Surgery on COVID-19: a Multicentric Study from a High Incidence Area
Federico Marchesi, Marina Valente, Matteo Riccò, et al.
Obesity Surgery (2021) Vol. 31, Iss. 6, pp. 2477-2488
Open Access | Times Cited: 33
COVID-19 pandemic and hypertension: an updated report from the Japanese Society of Hypertension project team on COVID-19
Shigeru Shibata, Kazuo Kobayashi, Masami Tanaka, et al.
Hypertension Research (2022) Vol. 46, Iss. 3, pp. 589-600
Open Access | Times Cited: 24
Association between angiotensin-converting enzyme inhibitors and the risk of lung cancer: a systematic review and meta-analysis
Zhenchao Wu, Taikang Yao, Zilu Wang, et al.
British Journal of Cancer (2022) Vol. 128, Iss. 2, pp. 168-176
Open Access | Times Cited: 21
Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research
Jordan Loader, Frances C. Taylor, Erik Lampa, et al.
Journal of the American Heart Association (2022) Vol. 11, Iss. 11
Open Access | Times Cited: 19
Effects of Renin–Angiotensin System Inhibitors on Mortality and Disease Severity of COVID-19 Patients: A Meta-analysis of Randomized Controlled Trials
Juntao Yin, Chaoyang Wang, Xiaoyong Song, et al.
American Journal of Hypertension (2022) Vol. 35, Iss. 5, pp. 462-469
Open Access | Times Cited: 18
Relationship between 2nd-generation angiotensin receptor blockers and the risk of hypotension in COVID-19 patients admitted to hospital
Fumiki Yoshihara, Yasushi Matsuzawa, Kiyomasa Nakatsuka, et al.
Hypertension Research (2024) Vol. 47, Iss. 7, pp. 1943-1951
Closed Access | Times Cited: 3
Relationship between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and COVID-19 incidence or severe disease
Gary Tse, Jiandong Zhou, Sharen Lee, et al.
Journal of Hypertension (2021) Vol. 39, Iss. 8, pp. 1717-1724
Open Access | Times Cited: 22
Overreactive macrophages in SARS-CoV-2 infection: The effects of ACEI
Dominik Felkle, Katarzyna Zięba, Konrad Kaleta, et al.
International Immunopharmacology (2023) Vol. 124, pp. 110858-110858
Open Access | Times Cited: 8
Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors
Terry Lee, Alessandro Cau, Matthew P. Cheng, et al.
CJC Open (2021) Vol. 3, Iss. 7, pp. 965-975
Open Access | Times Cited: 19
COVID‐19 and renin angiotensin aldosterone system: Pathogenesis and therapy
Fatemeh Babajani, Atefeh Kakavand, Hossien Mohammadi, et al.
Health Science Reports (2021) Vol. 4, Iss. 4
Open Access | Times Cited: 19
An umbrella review and meta‐analysis of renin–angiotensin system drugs use and COVID‐19 outcomes
Amanj Kurdi, Tanja Mueller, Natalie Weir
European Journal of Clinical Investigation (2022) Vol. 53, Iss. 2
Open Access | Times Cited: 12
Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity
Jorge Gonçalves, Catarina D. Santos, Paula Fresco, et al.
Revista Portuguesa de Cardiologia (2023) Vol. 42, Iss. 4, pp. 373-383
Open Access | Times Cited: 7
Development of a Risk Score for AKI onset in COVID-19 Patients: COV-AKI Score
Henrique Palomba, Daniel Caraca Cubos, Fernando A. Bozza, et al.
BMC Nephrology (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 6
Influence of angiotensin converting enzyme inhibitors/angiotensin receptor blockers on the risk of all‐cause mortality and other clinical outcomes in patients with confirmed COVID‐19: A systemic review and meta‐analysis
Na Jia, Guifang Zhang, Xuelin Sun, et al.
Journal of Clinical Hypertension (2021) Vol. 23, Iss. 9, pp. 1651-1663
Open Access | Times Cited: 15
Association of In-hospital Use of Statins, Aspirin, and Renin-Angiotensin-Aldosterone Inhibitors with Mortality and ICU Admission Due to COVID-19
Amir Vahedian‐Azimi, Farshid Rahimi‐Bashar, Ali Najafi, et al.
Advances in experimental medicine and biology (2021), pp. 205-214
Closed Access | Times Cited: 15
Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in hospitalized patients with COVID-19: an updated systematic review and meta-analysis of randomized clinical trials
Joseph Alexander Paguio, Bruce Adrian Casipit, Tara A John, et al.
Expert Review of Cardiovascular Therapy (2023) Vol. 21, Iss. 3, pp. 219-226
Closed Access | Times Cited: 5
Evaluation of pathophysiological relationships between renin-angiotensin and ACE-ACE2 systems in cardiovascular disorders: from theory to routine clinical practice in patients with heart failure
Alberto Aimo, Giuseppe Vergaro, Claudio Passino, et al.
Critical Reviews in Clinical Laboratory Sciences (2021) Vol. 58, Iss. 8, pp. 530-545
Closed Access | Times Cited: 13
The age again in the eye of the COVID-19 storm: evidence-based decision making
Carmen Martín, Aurora Jurado, Cristina Abad‐Molina, et al.
Immunity & Ageing (2021) Vol. 18, Iss. 1
Open Access | Times Cited: 9
Association of clinical characteristics, antidiabetic and cardiovascular agents with diabetes mellitus and COVID-19: a 7-month follow-up cohort study
Marzieh Pazoki, Fatemeh Chichagi, Azar Hadadi, et al.
Journal of Diabetes & Metabolic Disorders (2021) Vol. 20, Iss. 2, pp. 1545-1555
Open Access | Times Cited: 9
Update Alert 7: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults
Katherine Mackey, Devan Kansagara, Kathryn Vela
Annals of Internal Medicine (2021) Vol. 174, Iss. 2, pp. W25-W29
Open Access | Times Cited: 9
Association of outpatient use of renin–angiotensin–aldosterone system blockers on outcomes of acute respiratory illness during the COVID-19 pandemic: a cohort study
Molly M. Jeffery, Lucas Oliveira J. e Silva, Fernanda Bellolio, et al.
BMJ Open (2022) Vol. 12, Iss. 7, pp. e060305-e060305
Open Access | Times Cited: 6
Discontinuation of Antihypertensive Drug Use Compared to Continuation in COVID-19 Patients: A Systematic Review with Meta-analysis and Trial Sequential Analysis
Diego Chambergo‐Michilot, Fernando M. Runzer‐Colmenares, Pedro Segura-Saldaña
High Blood Pressure & Cardiovascular Prevention (2023) Vol. 30, Iss. 3, pp. 265-279
Open Access | Times Cited: 3
Initiation of antihypertensive drugs to patients with confirmed COVID‐19—A population‐based cohort study in Sweden
Salar Issa Mousa, Fredrik Nyberg, Mohammadhossein Hajiebrahimi, et al.
Basic & Clinical Pharmacology & Toxicology (2022) Vol. 131, Iss. 3, pp. 196-204
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top